The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Antifungal infection Therapeutics-Global Market Insights and Sales Trends 2025
Synopsis
Antifungal drugs are used to treat infections caused by fungus and to prevent the development of fungal infections in patients with weakened immune systems.
The global Antifungal infection Therapeutics market size is expected to reach US$ 29440 million by 2029, growing at a CAGR of 6.8% from 2023 to 2029. The market is mainly driven by the significant applications of Antifungal infection Therapeutics in various end use industries. The expanding demands from the Hospitals and Clinics and Dermatology Clinic, are propelling Antifungal infection Therapeutics market. Polyenes, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Echinocandins segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Antifungal infection Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Antifungal infection Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Antifungal infection Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Antifungal infection Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Antifungal infection Therapeutics covered in this report include Scynexis, Sanofi-Aventis, Pfizer, Novartis, Merck & Co, Kramer Laboratories, Johnson & Johnson, ID Sigma-Aldrich Corporation and Glenmark Pharmaceuticals, etc.
The global Antifungal infection Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Scynexis
Sanofi-Aventis
Pfizer
Novartis
Merck & Co
Kramer Laboratories
Johnson & Johnson
ID Sigma-Aldrich Corporation
Glenmark Pharmaceuticals
Glaxosmithkline
Enzon Pharmaceuticals
Bayer Healthcare
Astellas Pharma
Asperqillus
Alternaria
Abbott Laboratories
Global Antifungal infection Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Antifungal infection Therapeutics market, Segment by Type:
Polyenes
Echinocandins
Azoles
Allylamines
Other Drug types
Global Antifungal infection Therapeutics market, by Application
Hospitals and Clinics
Dermatology Clinic
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Antifungal infection Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Antifungal drugs are used to treat infections caused by fungus and to prevent the development of fungal infections in patients with weakened immune systems.
The global Antifungal infection Therapeutics market size is expected to reach US$ 29440 million by 2029, growing at a CAGR of 6.8% from 2023 to 2029. The market is mainly driven by the significant applications of Antifungal infection Therapeutics in various end use industries. The expanding demands from the Hospitals and Clinics and Dermatology Clinic, are propelling Antifungal infection Therapeutics market. Polyenes, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Echinocandins segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Antifungal infection Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Antifungal infection Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Antifungal infection Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Antifungal infection Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Antifungal infection Therapeutics covered in this report include Scynexis, Sanofi-Aventis, Pfizer, Novartis, Merck & Co, Kramer Laboratories, Johnson & Johnson, ID Sigma-Aldrich Corporation and Glenmark Pharmaceuticals, etc.
The global Antifungal infection Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Scynexis
Sanofi-Aventis
Pfizer
Novartis
Merck & Co
Kramer Laboratories
Johnson & Johnson
ID Sigma-Aldrich Corporation
Glenmark Pharmaceuticals
Glaxosmithkline
Enzon Pharmaceuticals
Bayer Healthcare
Astellas Pharma
Asperqillus
Alternaria
Abbott Laboratories
Global Antifungal infection Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Antifungal infection Therapeutics market, Segment by Type:
Polyenes
Echinocandins
Azoles
Allylamines
Other Drug types
Global Antifungal infection Therapeutics market, by Application
Hospitals and Clinics
Dermatology Clinic
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Antifungal infection Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Antifungal infection Therapeutics
1.1 Antifungal infection Therapeutics Market Overview
1.1.1 Antifungal infection Therapeutics Product Scope
1.1.2 Antifungal infection Therapeutics Market Status and Outlook
1.2 Global Antifungal infection Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Antifungal infection Therapeutics Market Size by Region (2018-2029)
1.4 Global Antifungal infection Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Antifungal infection Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Antifungal infection Therapeutics Market Size (2018-2029)
1.6.1 North America Antifungal infection Therapeutics Market Size (2018-2029)
1.6.2 Europe Antifungal infection Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Antifungal infection Therapeutics Market Size (2018-2029)
1.6.4 Latin America Antifungal infection Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Antifungal infection Therapeutics Market Size (2018-2029)
2 Antifungal infection Therapeutics Market by Type
2.1 Introduction
2.1.1 Polyenes
2.1.2 Echinocandins
2.1.3 Azoles
2.1.4 Allylamines
2.1.5 Other Drug types
2.2 Global Antifungal infection Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Antifungal infection Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Antifungal infection Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Antifungal infection Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Antifungal infection Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Antifungal infection Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Antifungal infection Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Antifungal infection Therapeutics Revenue Breakdown by Type (2018-2029)
3 Antifungal infection Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospitals and Clinics
3.1.2 Dermatology Clinic
3.2 Global Antifungal infection Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Antifungal infection Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Antifungal infection Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Antifungal infection Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Antifungal infection Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Antifungal infection Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Antifungal infection Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Antifungal infection Therapeutics Revenue Breakdown by Application (2018-2029)
4 Antifungal infection Therapeutics Competition Analysis by Players
4.1 Global Antifungal infection Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Antifungal infection Therapeutics as of 2022)
4.3 Date of Key Players Enter into Antifungal infection Therapeutics Market
4.4 Global Top Players Antifungal infection Therapeutics Headquarters and Area Served
4.5 Key Players Antifungal infection Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Antifungal infection Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Scynexis
5.1.1 Scynexis Profile
5.1.2 Scynexis Main Business
5.1.3 Scynexis Antifungal infection Therapeutics Products, Services and Solutions
5.1.4 Scynexis Antifungal infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 Scynexis Recent Developments
5.2 Sanofi-Aventis
5.2.1 Sanofi-Aventis Profile
5.2.2 Sanofi-Aventis Main Business
5.2.3 Sanofi-Aventis Antifungal infection Therapeutics Products, Services and Solutions
5.2.4 Sanofi-Aventis Antifungal infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Sanofi-Aventis Recent Developments
5.3 Pfizer
5.3.1 Pfizer Profile
5.3.2 Pfizer Main Business
5.3.3 Pfizer Antifungal infection Therapeutics Products, Services and Solutions
5.3.4 Pfizer Antifungal infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Novartis Recent Developments
5.4 Novartis
5.4.1 Novartis Profile
5.4.2 Novartis Main Business
5.4.3 Novartis Antifungal infection Therapeutics Products, Services and Solutions
5.4.4 Novartis Antifungal infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Novartis Recent Developments
5.5 Merck & Co
5.5.1 Merck & Co Profile
5.5.2 Merck & Co Main Business
5.5.3 Merck & Co Antifungal infection Therapeutics Products, Services and Solutions
5.5.4 Merck & Co Antifungal infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Merck & Co Recent Developments
5.6 Kramer Laboratories
5.6.1 Kramer Laboratories Profile
5.6.2 Kramer Laboratories Main Business
5.6.3 Kramer Laboratories Antifungal infection Therapeutics Products, Services and Solutions
5.6.4 Kramer Laboratories Antifungal infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Kramer Laboratories Recent Developments
5.7 Johnson & Johnson
5.7.1 Johnson & Johnson Profile
5.7.2 Johnson & Johnson Main Business
5.7.3 Johnson & Johnson Antifungal infection Therapeutics Products, Services and Solutions
5.7.4 Johnson & Johnson Antifungal infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Johnson & Johnson Recent Developments
5.8 ID Sigma-Aldrich Corporation
5.8.1 ID Sigma-Aldrich Corporation Profile
5.8.2 ID Sigma-Aldrich Corporation Main Business
5.8.3 ID Sigma-Aldrich Corporation Antifungal infection Therapeutics Products, Services and Solutions
5.8.4 ID Sigma-Aldrich Corporation Antifungal infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 ID Sigma-Aldrich Corporation Recent Developments
5.9 Glenmark Pharmaceuticals
5.9.1 Glenmark Pharmaceuticals Profile
5.9.2 Glenmark Pharmaceuticals Main Business
5.9.3 Glenmark Pharmaceuticals Antifungal infection Therapeutics Products, Services and Solutions
5.9.4 Glenmark Pharmaceuticals Antifungal infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 Glenmark Pharmaceuticals Recent Developments
5.10 Glaxosmithkline
5.10.1 Glaxosmithkline Profile
5.10.2 Glaxosmithkline Main Business
5.10.3 Glaxosmithkline Antifungal infection Therapeutics Products, Services and Solutions
5.10.4 Glaxosmithkline Antifungal infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Glaxosmithkline Recent Developments
5.11 Enzon Pharmaceuticals
5.11.1 Enzon Pharmaceuticals Profile
5.11.2 Enzon Pharmaceuticals Main Business
5.11.3 Enzon Pharmaceuticals Antifungal infection Therapeutics Products, Services and Solutions
5.11.4 Enzon Pharmaceuticals Antifungal infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.11.5 Enzon Pharmaceuticals Recent Developments
5.12 Bayer Healthcare
5.12.1 Bayer Healthcare Profile
5.12.2 Bayer Healthcare Main Business
5.12.3 Bayer Healthcare Antifungal infection Therapeutics Products, Services and Solutions
5.12.4 Bayer Healthcare Antifungal infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.12.5 Bayer Healthcare Recent Developments
5.13 Astellas Pharma
5.13.1 Astellas Pharma Profile
5.13.2 Astellas Pharma Main Business
5.13.3 Astellas Pharma Antifungal infection Therapeutics Products, Services and Solutions
5.13.4 Astellas Pharma Antifungal infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.13.5 Astellas Pharma Recent Developments
5.14 Asperqillus
5.14.1 Asperqillus Profile
5.14.2 Asperqillus Main Business
5.14.3 Asperqillus Antifungal infection Therapeutics Products, Services and Solutions
5.14.4 Asperqillus Antifungal infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.14.5 Asperqillus Recent Developments
5.15 Alternaria
5.15.1 Alternaria Profile
5.15.2 Alternaria Main Business
5.15.3 Alternaria Antifungal infection Therapeutics Products, Services and Solutions
5.15.4 Alternaria Antifungal infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.15.5 Alternaria Recent Developments
5.16 Abbott Laboratories
5.16.1 Abbott Laboratories Profile
5.16.2 Abbott Laboratories Main Business
5.16.3 Abbott Laboratories Antifungal infection Therapeutics Products, Services and Solutions
5.16.4 Abbott Laboratories Antifungal infection Therapeutics Revenue (US$ Million) & (2018-2023)
5.16.5 Abbott Laboratories Recent Developments
6 North America
6.1 North America Antifungal infection Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Antifungal infection Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Antifungal infection Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Antifungal infection Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Antifungal infection Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Antifungal infection Therapeutics Market Dynamics
11.1 Antifungal infection Therapeutics Industry Trends
11.2 Antifungal infection Therapeutics Market Drivers
11.3 Antifungal infection Therapeutics Market Challenges
11.4 Antifungal infection Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
